Abstract
Identification of patients with a poor prognosis for non-metastatic rhabdomyosarcoma (RMS) remains a clinical challenge. Prospective analysis for the presence of disseminated RMS cells in bone marrow at diagnosis, using immunocytochemistry, with MyoD1 and myogenin as markers, was carried out. Thirty-seven patients treated on RMS88 and RMS96 Italian protocols underwent staging investigations, and in addition marrow examination for occult tumour cells. All patients had negative marrow involvement using cytomorphology, but 10/37 were positive with immunostaining. With a median follow-up of 46 months (range, 12-115), 7 patients had died and 30 were disease-free. Overall survival probability was 92% in patients with no occult marrow infiltration, 47% with occult marrow infiltration (P = 0.001); event-free survival probability was 89% in the former and 50% in the latter (P = 0.01). Disseminated tumour cells are indicative of disease spread and are significantly linked to recurrence at distant sites and poorer outcome. Marrow examination at diagnosis using immunocytochemistry may be an additional tool to modulate treatment.
| Original language | English |
|---|---|
| Pages (from-to) | 2288-2296 |
| Number of pages | 9 |
| Journal | European Journal of Cancer |
| Volume | 41 |
| Issue number | 15 |
| DOIs | |
| Publication status | Published - Oct 2005 |
Fingerprint
Keywords
- Disseminated tumour cells
- MyoD1
- Myogenic regulatory factors
- Myogenin
- Rhabdomyosarcoma
ASJC Scopus subject areas
- Cancer Research
- Hematology
- Oncology
Cite this
Detection and clinical significance of disseminated tumour cells at diagnosis in bone marrow of children with localised rhabdomyosarcoma. / McDowell, Heather P.; Donfrancesco, Alberto; Milano, Giuseppe M.; Clerico, Anna; Mannarino, Olga; Altavista, Pierluigi; Boldrini, Renata; Cozza, Raffaele; Inserra, Alessandro; Dominici, Carlo.
In: European Journal of Cancer, Vol. 41, No. 15, 10.2005, p. 2288-2296.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Detection and clinical significance of disseminated tumour cells at diagnosis in bone marrow of children with localised rhabdomyosarcoma
AU - McDowell, Heather P.
AU - Donfrancesco, Alberto
AU - Milano, Giuseppe M.
AU - Clerico, Anna
AU - Mannarino, Olga
AU - Altavista, Pierluigi
AU - Boldrini, Renata
AU - Cozza, Raffaele
AU - Inserra, Alessandro
AU - Dominici, Carlo
PY - 2005/10
Y1 - 2005/10
N2 - Identification of patients with a poor prognosis for non-metastatic rhabdomyosarcoma (RMS) remains a clinical challenge. Prospective analysis for the presence of disseminated RMS cells in bone marrow at diagnosis, using immunocytochemistry, with MyoD1 and myogenin as markers, was carried out. Thirty-seven patients treated on RMS88 and RMS96 Italian protocols underwent staging investigations, and in addition marrow examination for occult tumour cells. All patients had negative marrow involvement using cytomorphology, but 10/37 were positive with immunostaining. With a median follow-up of 46 months (range, 12-115), 7 patients had died and 30 were disease-free. Overall survival probability was 92% in patients with no occult marrow infiltration, 47% with occult marrow infiltration (P = 0.001); event-free survival probability was 89% in the former and 50% in the latter (P = 0.01). Disseminated tumour cells are indicative of disease spread and are significantly linked to recurrence at distant sites and poorer outcome. Marrow examination at diagnosis using immunocytochemistry may be an additional tool to modulate treatment.
AB - Identification of patients with a poor prognosis for non-metastatic rhabdomyosarcoma (RMS) remains a clinical challenge. Prospective analysis for the presence of disseminated RMS cells in bone marrow at diagnosis, using immunocytochemistry, with MyoD1 and myogenin as markers, was carried out. Thirty-seven patients treated on RMS88 and RMS96 Italian protocols underwent staging investigations, and in addition marrow examination for occult tumour cells. All patients had negative marrow involvement using cytomorphology, but 10/37 were positive with immunostaining. With a median follow-up of 46 months (range, 12-115), 7 patients had died and 30 were disease-free. Overall survival probability was 92% in patients with no occult marrow infiltration, 47% with occult marrow infiltration (P = 0.001); event-free survival probability was 89% in the former and 50% in the latter (P = 0.01). Disseminated tumour cells are indicative of disease spread and are significantly linked to recurrence at distant sites and poorer outcome. Marrow examination at diagnosis using immunocytochemistry may be an additional tool to modulate treatment.
KW - Disseminated tumour cells
KW - MyoD1
KW - Myogenic regulatory factors
KW - Myogenin
KW - Rhabdomyosarcoma
UR - http://www.scopus.com/inward/record.url?scp=26244457590&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=26244457590&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2005.07.007
DO - 10.1016/j.ejca.2005.07.007
M3 - Article
VL - 41
SP - 2288
EP - 2296
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
IS - 15
ER -